Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1774MR)

This product GTTS-WQ1774MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1774MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6084MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ6994MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ7368MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ3378MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ13923MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ6708MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ7629MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ4123MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW